Entrada Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRDA research report →
About the company
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
- CEO
- Dipal Doshi
- IPO
- 2021
- Employees
- 183
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $299.70M
- P/E
- -1.93
- P/S
- 52.23
- P/B
- 1.19
- EV/EBITDA
- -1.66
- Div Yield
- 0.00%
- Gross Margin
- -598.01%
- Op Margin
- -3109.29%
- Net Margin
- -2895.05%
- ROE
- -51.22%
- ROIC
- -55.65%
- Revenue
- $25.42M · -87.94%
- Net Income
- $-143,750,000 · -319.04%
- EPS
- $-3.47 · -297.16%
- Op Income
- $-155,998,000
- FCF YoY
- -189.73%
- 52W High
- $16.45
- 52W Low
- $4.93
- 50D MA
- $8.35
- 200D MA
- $9.54
- Beta
- -0.26
- Avg Volume
- 394.09K
Get TickerSpark's AI analysis on TRDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | PARMAR KUSH | other | 19,000 |
| Jun 10, 26 | KIM PETER S | other | 19,000 |
| Jun 10, 26 | Chapman Gina | other | 19,000 |
| Jun 10, 26 | Radhakrishnan Maha | other | 19,000 |
| Jun 10, 26 | Thistle Mary | other | 19,000 |
| Jun 10, 26 | Zeiher Bernhardt G | other | 19,000 |
| May 20, 26 | Zeiher Bernhardt G | buy | 5,000 |
| May 4, 26 | Sethuraman Natarajan | sell | 25,907 |
| May 4, 26 | Dowden Nathan J | other | 15,000 |
| May 4, 26 | Dowden Nathan J | sell | 15,000 |
Our TRDA coverage
Recent articles, reports, and earnings notes.
No research on TRDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRDA report →Similar companies
Peers in the same neighborhood.